NASDAQ$AKYA

Akoya Biosciences Inc · Q1 2022 earnings

Q1 2022 earnings · · Investor relations

Briefing

Akoya reported record revenue and system placements, driven by the commercial launch of the PhenoCycler-Fusion System and execution across all business segments.

Akoya Biosciences reported a 38% increase in total revenue for Q1 2022, reaching $16.9 million compared to $12.2 million in the prior year period. The company also raised its full year 2022 revenue guidance to a range of $70-73 million.

  • Total revenue increased by 38% to $16.9 million compared to the prior year period.
  • Product revenue increased by 34% to $13.3 million, with reagent revenue increasing by 82%.
  • Services and other revenue increased by 58% to $3.6 million.
  • Gross profit increased by 36% to $10.1 million, with a gross profit margin of 60%.

Headline financials

Total Revenue

$16.9M

Previous: $12.2M+38.3%
EPS (adj)

-$0.44

Previous: -$3.54+87.6%
Capital Expenditures

$1.14M

Previous: $907K+25.5%
Free Cash Flow

-$19.1M

Previous: -$5.31M-259.1%
Net Income

-$16.4M

Previous: -$8.08M-102.9%
Operating Income

-$15.6M

Previous: -$5.4M-188.0%
Gross Profit

$10.1M

Previous: $7.41M+36.3%
Cash & Equivalents

$93.9M

Previous: $11.7M+703.5%
Total Assets

$187M

Previous: $74.5M+151.2%
Stock-Based Comp

$1.55M

Previous: $254K+508.3%

Revenue & EPS history

Akoya · Revenue · Quarterly

$16.9M

Q1 2022+38.3%vs Q1 2021
Beat estimate in 9 of 15 quarters(60%)
ActualEstimate

Revenue by segment

Akoya · $16.9M total across 2 segments · Q1 2022

  • Product revenue
    $13.3M+33.4%
  • Service and other revenue
    $3.55M+61.4%

Forward guidance

The company is raising its full year 2022 revenue guidance range to $70-73 million.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 10 quarterly earnings reports

Historical avg

-3.7%

Avg return

Earnings day

-8.6%

Avg return

5 days after

-17.2%

Avg return

30 days after

53%

10 / 19 earnings

Positive

+13.7%

Q4 2021

Best reaction

-31.9%

Q1 2024

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q3 2025
Q2 2025
Q1 2025+1.0%+24.8%+23.8%
Q4 2025+3.8%+9.2%-30.7%
Q3 2024-24.9%-33.2%-29.5%
Q2 2024-9.5%-0.9%+5.5%
Q1 2024-31.9%-35.1%-50.0%
Q4 2023-15.4%-17.1%-28.1%
Q3 2023+10.0%+6.9%+16.4%
Q2 2023+0.9%-6.5%-23.9%
Q1 2023-2.5%-17.1%-18.8%
Q4 2022-7.3%-17.2%-36.6%
Q3 2022-15.1%
Q2 2022+5.0%
Q1 2022-11.9%
Q4 2021+13.7%
Q3 2020+1.5%
Q3 2021+0.2%
Q2 2021-0.1%
Q4 2020+9.5%
Q1 2021+2.3%
Q2 2020
Q1 2020

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro